BioNTech SE (BioNTech SE) Construction In Progress : $425 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Construction In Progress?

BioNTech SE's quarterly construction in progress stayed the same from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($425 Mil).

BioNTech SE's annual construction in progress increased from Dec. 2021 ($107 Mil) to Dec. 2022 ($249 Mil) and increased from Dec. 2022 ($249 Mil) to Dec. 2023 ($425 Mil).

BioNTech SE Construction In Progress Historical Data

The historical data trend for BioNTech SE's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Construction In Progress Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

32.95

112.41

106.55

249.47

424.76

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Construction In Progress	Get a 7-Day Free Trial															249.47	-	-	-	424.76

BioNTech SE Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.